RJA
PBYI icon

Raymond James & Associates’s Puma Biotechnology PBYI Stock Holding History

Raymond James & Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,000
Closed -$111K – 3848
2020
Q3 		$111K Buy
+11,000
New +$112K ﹤0.01% 3364
2018
Q3 		– Sell
-7,693
Closed -$455K – 3695
2018
Q2 		$455K Buy
7,693
+3,303
+75% +$191K ﹤0.01% 2744
2018
Q1 		$299K Buy
4,390
+140
+3% +$10.5K ﹤0.01% 2881
2017
Q4 		$420K Buy
+4,250
New +$476K ﹤0.01% 2640
2016
Q4 		– Sell
-23,078
Closed -$1.55M – 3330
2016
Q3 		$1.55M Buy
+23,078
New +$1.17M ﹤0.01% 1616

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Raymond James & Associates's PBYI Position: Q4 2020 in Review

Raymond James & Associates sold out of Puma Biotechnology (PBYI) in Q4 2020, closing a stake of 11,000 shares — an estimated $111K sold.

Raymond James & Associates first reported a position in PBYI in Q3 2016 and held it in 5 quarters. The position peaked at $1.55M in Q3 2016. 123 funds tracked by Wall St. Rank hold PBYI as of Q4 2020.

  • Raymond James & Associates reported no remaining Puma Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 11,000 Puma Biotechnology shares in Q4 2020, an estimated $111K.
  • Raymond James & Associates first reported a position in Puma Biotechnology in Q3 2016 and held it in 5 quarters.
  • Raymond James & Associates's Puma Biotechnology position peaked at $1.55M in Q3 2016.
  • 123 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.